These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

696 related items for PubMed ID: 26364896

  • 1. The use of stimulants and atomoxetine in adults with comorbid ADHD and bipolar disorder.
    Perugi G, Vannucchi G.
    Expert Opin Pharmacother; 2015; 16(14):2193-204. PubMed ID: 26364896
    [Abstract] [Full Text] [Related]

  • 2. Current and emerging pharmacotherapy for the treatment of adult attention deficit hyperactivity disorder (ADHD).
    Perugi G, Pallucchini A, Rizzato S, Pinzone V, De Rossi P.
    Expert Opin Pharmacother; 2019 Aug; 20(12):1457-1470. PubMed ID: 31112441
    [Abstract] [Full Text] [Related]

  • 3. A systematic review of pharmacotherapy for attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders.
    Pouchon A, Nasserdine R, Dondé C, Bertrand A, Polosan M, Bioulac S.
    Expert Opin Pharmacother; 2023 Aug; 24(13):1497-1509. PubMed ID: 37300473
    [Abstract] [Full Text] [Related]

  • 4. Attention-deficit hyperactivity disorder, its pharmacotherapy, and the risk of developing bipolar disorder: A nationwide population-based study in Taiwan.
    Wang LJ, Shyu YC, Yuan SS, Yang CJ, Yang KC, Lee TL, Lee SY.
    J Psychiatr Res; 2016 Jan; 72():6-14. PubMed ID: 26519764
    [Abstract] [Full Text] [Related]

  • 5. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid attention-deficit/hyperactivity disorder.
    Bond DJ, Hadjipavlou G, Lam RW, McIntyre RS, Beaulieu S, Schaffer A, Weiss M, Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force.
    Ann Clin Psychiatry; 2012 Feb; 24(1):23-37. PubMed ID: 22303520
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. The complexity of ADHD: diagnosis and treatment of the adult patient with comorbidities.
    Newcorn JH, Weiss M, Stein MA.
    CNS Spectr; 2007 Aug; 12(8 Suppl 12):1-14; quiz 15-6. PubMed ID: 17667893
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Adult ADHD: clinical aspects and therapeutic implications].
    Ceraudo G, Vannucchi G, Perugi G, Dell'osso L.
    Riv Psichiatr; 2012 Aug; 47(6):451-64. PubMed ID: 23160106
    [Abstract] [Full Text] [Related]

  • 11. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder in children and adolescents with bipolar disorders.
    Hah M, Chang K.
    J Child Adolesc Psychopharmacol; 2005 Dec; 15(6):996-1004. PubMed ID: 16379520
    [Abstract] [Full Text] [Related]

  • 12. ADHD with Comorbid Bipolar Disorders: A Systematic Review of Neurobiological, Clinical and Pharmacological Aspects Across the Lifespan.
    Mucci F, Avella MT, Marazziti D.
    Curr Med Chem; 2019 Dec; 26(38):6942-6969. PubMed ID: 31385763
    [Abstract] [Full Text] [Related]

  • 13. Effects of stimulants and atomoxetine on emotional lability in adults: A systematic review and meta-analysis.
    Moukhtarian TR, Cooper RE, Vassos E, Moran P, Asherson P.
    Eur Psychiatry; 2017 Jul; 44():198-207. PubMed ID: 28646732
    [Abstract] [Full Text] [Related]

  • 14. A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.
    Kollins SH.
    Curr Med Res Opin; 2008 May; 24(5):1345-57. PubMed ID: 18384709
    [Abstract] [Full Text] [Related]

  • 15. Concomitant use of atomoxetine and OROS-methylphenidate in a 10-year-old child suffering from attention-deficit/hyperactivity disorder with comorbid bipolar disorder and Tourette syndrome.
    Jaworowski S, Benarroch F, Gross-Tsur V.
    J Child Adolesc Psychopharmacol; 2006 Jun; 16(3):365-70. PubMed ID: 16768644
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Comparative efficacy and safety of methylphenidate and atomoxetine for attention-deficit hyperactivity disorder in children and adolescents: Meta-analysis based on head-to-head trials.
    Liu Q, Zhang H, Fang Q, Qin L.
    J Clin Exp Neuropsychol; 2017 Nov; 39(9):854-865. PubMed ID: 28052720
    [Abstract] [Full Text] [Related]

  • 19. [Adult attention deficit hyperactivity disorder (ADHD) with comorbid addictive disorder. Therapeutic challenges using the example of a survey of clinical practice].
    Adorjan K, Karch S, Martin G, Plörer D, Winter C, Hantschk I, Koller G, Erbas B, Pogarell O.
    MMW Fortschr Med; 2019 Jul; 161(Suppl 5):7-12. PubMed ID: 31313269
    [Abstract] [Full Text] [Related]

  • 20. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY, Pan YL, Lin HY, Huang LW, Gau SS.
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 35.